These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 15882358)

  • 21. Immunotherapy as treatment for Alzheimer's disease.
    Hawkes CA; McLaurin J
    Expert Rev Neurother; 2007 Nov; 7(11):1535-48. PubMed ID: 17997702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid-dependent triosephosphate isomerase nitrotyrosination induces glycation and tau fibrillation.
    Guix FX; Ill-Raga G; Bravo R; Nakaya T; de Fabritiis G; Coma M; Miscione GP; Villà-Freixa J; Suzuki T; Fernàndez-Busquets X; Valverde MA; de Strooper B; Muñoz FJ
    Brain; 2009 May; 132(Pt 5):1335-45. PubMed ID: 19251756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alzheimer's disease: Moving towards a vaccine.
    Holtzman DM
    Nature; 2008 Jul; 454(7203):418-20. PubMed ID: 18650906
    [No Abstract]   [Full Text] [Related]  

  • 24. Beta-amyloid immunisation in Alzheimer's disease.
    Sorbi S
    Neurol Sci; 2005 May; 26 Suppl 1():S5. PubMed ID: 15883696
    [No Abstract]   [Full Text] [Related]  

  • 25. Clearing tau pathology with Abeta immunotherapy--reversible and irreversible stages revealed.
    Hutton M; McGowan E
    Neuron; 2004 Aug; 43(3):293-4. PubMed ID: 15294135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease.
    Dodel R; Hampel H; Depboylu C; Lin S; Gao F; Schock S; Jäckel S; Wei X; Buerger K; Höft C; Hemmer B; Möller HJ; Farlow M; Oertel WH; Sommer N; Du Y
    Ann Neurol; 2002 Aug; 52(2):253-6. PubMed ID: 12210803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.
    Wang YJ; Zhou HD; Zhou XF
    Drug Discov Today; 2006 Oct; 11(19-20):931-8. PubMed ID: 16997144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice.
    Morgan D
    Neurochem Int; 2006 Jul; 49(2):190-4. PubMed ID: 16740342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing.
    Ryan JM; Grundman M
    J Alzheimers Dis; 2009; 17(2):243. PubMed ID: 19502708
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
    Rakover I; Arbel M; Solomon B
    Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden.
    Kellner A; Matschke J; Bernreuther C; Moch H; Ferrer I; Glatzel M
    Ann Neurol; 2009 Jan; 65(1):24-31. PubMed ID: 19194878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions.
    McGeer EG; McGeer PL
    Mol Interv; 2001 Apr; 1(1):22-9. PubMed ID: 14993335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo.
    Gaugler MN; Tracy J; Kuhnle K; Crameri A; Nitsch RM; Mohajeri MH
    FEBS Lett; 2005 Jan; 579(3):753-6. PubMed ID: 15670841
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyloid-beta immunotherapies in mice and men.
    Brendza RP; Holtzman DM
    Alzheimer Dis Assoc Disord; 2006; 20(2):118-23. PubMed ID: 16772748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-amyloid immunotherapy in Alzheimer's disease].
    Orgogozo JM
    Rev Neurol (Paris); 2008 Apr; 164 Spec No 2():F95-7. PubMed ID: 18680825
    [No Abstract]   [Full Text] [Related]  

  • 36. Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease?
    Klausner AP; Sharma S; Fletcher S; Neff P; Yang SK; Son H; Tuttle JB; Steers WD
    J Urol; 2008 Mar; 179(3):1173-7. PubMed ID: 18206173
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active immunization against Alzheimer's beta-amyloid peptide using phage display technology.
    Solomon B
    Vaccine; 2007 Apr; 25(16):3053-6. PubMed ID: 17287054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques.
    Poduslo JF; Ramakrishnan M; Holasek SS; Ramirez-Alvarado M; Kandimalla KK; Gilles EJ; Curran GL; Wengenack TM
    J Neurochem; 2007 Jul; 102(2):420-33. PubMed ID: 17596213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amyloid imaging in Alzheimer's disease.
    Nordberg A
    Neuropsychologia; 2008; 46(6):1636-41. PubMed ID: 18468648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety.
    Okura Y; Miyakoshi A; Kohyama K; Park IK; Staufenbiel M; Matsumoto Y
    Proc Natl Acad Sci U S A; 2006 Jun; 103(25):9619-24. PubMed ID: 16769900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.